thalidomide has been researched along with Adjuvant Arthritis in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We assessed the anti-inflammatory effects of a novel PDE4 inhibitor, apremilast, in human synovial cells from rheumatoid arthritis (RA) patients, as well as two murine models of arthritis." | 3.76 | Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. ( Andrews, M; Brennan, FM; Feldmann, M; Inglis, JJ; McCann, FE; Palfreeman, AC; Perocheau, DP; Schafer, P; Williams, RO, 2010) |
| "Thalidomide is an immunomodulatory drug (IMiD) with proven therapeutic action in several autoimmune/inflammatory diseases; however, its inherent high toxicity has led to the development of more powerful and safer thalidomide analogs, including lenalidomide and pomalidomide." | 1.46 | Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. ( Criado, G; Delgado, M; Diaz de la Guardia, R; García-Herrero, CM; Gonzalez-Rey, E; Lavoie, JR; Lopez-Millan, B; Menendez, P; O'Valle, F; Roca-Ho, H; Rosu-Myles, M, 2017) |
| "Thalidomide was used as treatment in colitis and arthritis group, whereas etoricoxib was used in CWG group." | 1.36 | Correlation of seizures and biochemical parameters of oxidative stress in experimentally induced inflammatory rat models. ( Khanduja, KL; Medhi, B; Pandhi, P; Rao, RS, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lopez-Millan, B | 1 |
| Diaz de la Guardia, R | 1 |
| Roca-Ho, H | 1 |
| García-Herrero, CM | 1 |
| Lavoie, JR | 1 |
| Rosu-Myles, M | 1 |
| Gonzalez-Rey, E | 1 |
| O'Valle, F | 1 |
| Criado, G | 1 |
| Delgado, M | 1 |
| Menendez, P | 1 |
| McCann, FE | 1 |
| Palfreeman, AC | 1 |
| Andrews, M | 1 |
| Perocheau, DP | 1 |
| Inglis, JJ | 1 |
| Schafer, P | 1 |
| Feldmann, M | 1 |
| Williams, RO | 1 |
| Brennan, FM | 1 |
| Rao, RS | 1 |
| Medhi, B | 1 |
| Khanduja, KL | 1 |
| Pandhi, P | 1 |
| Bressan, E | 1 |
| Mitkovski, M | 1 |
| Tonussi, CR | 1 |
| Alexandre-Moreira, MS | 1 |
| Takiya, CM | 1 |
| de Arruda, LB | 1 |
| Pascarelli, B | 1 |
| Gomes, RN | 1 |
| Castro Faria Neto, HC | 1 |
| Lima, LM | 1 |
| Barreiro, EJ | 1 |
| Vale, ML | 1 |
| Cunha, FQ | 1 |
| Brito, GA | 1 |
| Benevides, VM | 1 |
| Ferreira, SH | 1 |
| Poole, S | 1 |
| Ribeiro, RA | 1 |
| Oliver, SJ | 1 |
| Freeman, SL | 1 |
| Corral, LG | 1 |
| Ocampo, CJ | 1 |
| Kaplan, G | 1 |
| Goihman-Yahr, M | 1 |
| Convit, J | 1 |
| Rodríguez-Ochoa, G | 1 |
| Aranzazu, N | 1 |
| Villalba-Pimentel, L | 1 |
| Ocanto, A | 1 |
| de Gómez, ME | 1 |
8 other studies available for thalidomide and Adjuvant Arthritis
| Article | Year |
|---|---|
Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Collagen Type II; Dextran Sulfate; Disea | 2017 |
Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Cells, Cultured; Disease Models, Animal; Do | 2010 |
Correlation of seizures and biochemical parameters of oxidative stress in experimentally induced inflammatory rat models.
Topics: Animals; Arthritis, Experimental; Colitis; Disease Models, Animal; Granuloma; Inflammation; Lipid Pe | 2010 |
LPS-induced knee-joint reactive arthritis and spinal cord glial activation were reduced after intrathecal thalidomide injection in rats.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Dose-Response Relationship, Drug; Escher | 2010 |
LASSBio-468: a new achiral thalidomide analogue which modulates TNF-alpha and NO production and inhibits endotoxic shock and arthritis in an animal model.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Gene Expression; Indoles; Isoindoles; Li | 2005 |
Anti-nociceptive effect of thalidomide on zymosan-induced experimental articular incapacitation.
Topics: Analgesics; Animals; Arthralgia; Arthritis, Experimental; Chemokine CXCL1; Chemokines, CXC; Exudates | 2006 |
Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis.
Topics: Animals; Arthritis, Experimental; Edema; Extremities; Female; Interleukin-2; Leukocytes; Lymphocyte | 1999 |
Significance of neutrophil activation in reactional lepromatous leprosy: effects of thalidomide in vivo and in vitro. Activation in adjuvant disease.
Topics: Arthritis; Arthritis, Experimental; Leprosy; Lymphocyte Activation; Neutrophils; Thalidomide | 1978 |